公开(公告)号：WO2008116103A2

公开(公告)日：2008-09-25

申请号：PCT/US2008/057718

申请日：2008-03-20

Applicant: IMCLONE SYSTEMS INCORPORATED ,  SRIVASTAVA, Arvind ,  GOLDSTEIN, Joel

Inventor： SRIVASTAVA, Arvind ,  GOLDSTEIN, Joel

IPC: A61K39/395

CPC classification number: A61K39/39591 ,  C07K16/2863

Abstract: The present invention provides formulations and methods for the stabilization of antibodies. In one embodiment, the invention provides the stable solution formulation of an IgG1 antibody that specifically binds to insulin-like growth factor-I receptor. In another embodiment, the invention provides methods of stabilization of IgG1 antibody that specifically binds to insulin-like growth factor-I receptor comprising lyophilizing an aqueous formulation of the antibody. The formulations can be lyophilized to stabilize the antibodies during processing and storage, and then the formulations can be reconstituted for pharmaceutical administration.

Abstract translation: 本发明提供用于稳定抗体的制剂和方法。 在一个实施方案中，本发明提供了与胰岛素样生长因子-I受体特异性结合的IgG1抗体的稳定溶液制剂。 在另一个实施方案中，本发明提供了特异性结合胰岛素样生长因子-I受体的IgG1抗体的稳定化方法，其包括将抗体的水性制剂冻干。 制剂可以在加工和储存期间被冻干以稳定抗体，然后可以将制剂重新配制用于药物施用。

公开(公告)号：WO2007092453A3

公开(公告)日：2007-08-16

申请号：PCT/US2007/003164

申请日：2007-02-03

Applicant: IMCLONE SYSTEMS INCORPORATED ,  UNIVERSITY OF WASHINGTON ,  LUDWIG, Dale ,  PLYMATE, Stephen, R.

Inventor： LUDWIG, Dale ,  PLYMATE, Stephen, R.

IPC: C12Q1/68 ,  C12P19/34 ,  C12N15/63 ,  A61K38/00 ,  C07K1/00 ,  C07H21/02 ,  C07H21/04 ,  A01N43/04

Abstract: The present invention relates to a method of treating prostate cancer with androgen deprivation therapy and an insulin-like growth factor receptor (IGF-IR) antagonist. Although the response rate of prostate cancer to androgen deprivation therapy (ADT) is high, surviving cancer cells invariably become androgen independent (AI) and tumor growth follows. The invention inhibits or delays transition of androgen dependent cancer to androgen independent cancer, significantly decreases risk of recurrence, and improves treatment outcome.

公开(公告)号：WO2005042496A1

公开(公告)日：2005-05-12

申请号：PCT/US2004/034672

申请日：2004-10-21

Applicant: IMCLONE SYSTEMS INCORPORATED ,  LIU, Hu ,  PAN, Weitao ,  XU, Yong-Jiang

Inventor： LIU, Hu ,  PAN, Weitao ,  XU, Yong-Jiang

IPC: C07D235/18

CPC classification number: C07D401/14 ,  C07D235/14 ,  C07D235/16 ,  C07D235/30 ,  C07D403/12 ,  C07D405/12 ,  C07D417/12

Abstract: The present invention encompasses heparanase inhibitors, particularly to certain (benzimidazol-2-yl)-phenyl-benzyl-amine derivatives that inhibit heparanase, pharmaceutical compositions that contain the compounds, methods for making the compounds, and methods of treating heparanase-dependent diseases and conditions in mammals by administering a therapeutically effective amount of the compounds to the mammals.

Abstract translation: 本发明包括乙酰肝素酶抑制剂，特别是抑制乙酰肝素酶的某些（苯并咪唑-2-基） - 苯基 - 苄基 - 胺衍生物，含有这些化合物的药物组合物，制备该化合物的方法，以及治疗乙酰肝素酶依赖性疾病的方法和 哺乳动物通过向哺乳动物施用治疗有效量的化合物的条件。

公开(公告)号：WO2005030206A1

公开(公告)日：2005-04-07

申请号：PCT/US2004/031689

申请日：2004-09-24

Applicant: IMCLONE SYSTEMS INCORPORATED ,  LIU, Hu ,  MIAO, Hua-Quan

Inventor： LIU, Hu ,  MIAO, Hua-Quan

IPC: A61K31/437

CPC classification number: C04B35/632 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D407/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04

Abstract: The present invention encompasses heparanase inhibitors, particularly to certain 2-substituted heteroaryl-fused and aryl-fused carbazole derivatives that inhibit heparanase, pharmaceutical compositions that contain the compounds, methods for making the compounds, and methods of treating heparanase-dependent diseases and conditions in mammals by administering a therapeutically effective amount of the compounds to the mammals.

Abstract translation: 本发明包括乙酰肝素酶抑制剂，特别是抑制乙酰肝素酶的某些2-取代杂芳基稠合和芳基稠合的咔唑衍生物，含有这些化合物的药物组合物，制备该化合物的方法，以及治疗乙酰肝素酶依赖性疾病和病症的方法 哺乳动物通过向哺乳动物施用治疗有效量的化合物。

公开(公告)号：WO2004003165A2

公开(公告)日：2004-01-08

申请号：PCT/US2003/020601

申请日：2003-06-30

Applicant: IMCLONE SYSTEMS INCORPORATED ,  PEREIRA, Daniel

Inventor： PEREIRA, Daniel

IPC: C12N

CPC classification number: C07K14/70503 ,  A61K38/00 ,  A61K2039/505

Abstract: The present invention provides a purified nucleic acid encoding a putative transmembrane receptor polypeptide comprising at its N-terminus leucine rich repeats and at least an immunoglobulin domain. S30-21616/DEGA polypeptide of the present invention, analogs of said polypeptide, vectors and host cells that embody the polynucleotides, bio-immunopharmaceutical compositions and diagnostic reagents comprising the polypeptides, analogs and derivatives and methods for making and utilizing the polypeptides are disclosed.

Abstract translation: 本发明提供了编码推定的跨膜受体多肽的纯化核酸，其在其N末端含有富含亮氨酸的重复序列和至少一个免疫球蛋白结构域。 公开了本发明的S30-21616 / DEGA多肽，所述多肽的类似物，体现多核苷酸的载体和宿主细胞，生物免疫药物组合物和包含多肽，类似物和衍生物的诊断试剂以及用于制备和利用多肽的方法。

公开(公告)号：WO1998025946A1

公开(公告)日：1998-06-18

申请号：PCT/US1997020006

申请日：1997-11-05

Applicant: IMCLONE SYSTEMS INCORPORATED ,  DEJANA, Elisabetta ,  TELO, Paola

Inventor： IMCLONE SYSTEMS INCORPORATED

IPC: C07H21/04

CPC classification number: C07K16/28 ,  A01K2217/05 ,  A01K2217/075 ,  A61K38/00 ,  C07K14/70596

Abstract: A new VE-cadherin molecule is provided. Monoclonal antibodies that specifically bind to and neutralize an extracellular domain of a VE-cadherin molecule are provided. In vitro and in vivo methods of using these antibodies are also provided.

Abstract translation: 提供了新的VE-钙粘蛋白分子。 提供了特异性结合并中和VE-钙粘蛋白分子的细胞外结构域的单克隆抗体。 还提供了使用这些抗体的体外和体内方法。

公开(公告)号：WO1996040176A1

公开(公告)日：1996-12-19

申请号：PCT/US1996009605

申请日：1996-06-07

Applicant: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH ,  ImCLONE SYSTEMS INCORPORATED

Inventor： SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH ,  ImCLONE SYSTEMS INCORPORATED ,  HOUGHTON, Alan, N. ,  GOLDSTEIN, Neil

IPC: A61K35/26

CPC classification number: A61K39/395 ,  A61K38/2013 ,  A61K35/14 ,  A61K35/26 ,  A61K35/28 ,  A61K2300/00

Abstract: This invention provides a pharmaceutical composition comprising effective amount of monoclonal antibody TA99, effective amount of interleukin-2 and a pharmaceutically acceptable carrier. This invention further provides the above composition further comprising lymphokine activated killer cells.

Abstract translation: 本发明提供了包含有效量的单克隆抗体TA99，有效量的白细胞介素-2和药学上可接受的载体的药物组合物。 本发明还提供了进一步包含淋巴因子活化的杀伤细胞的上述组合物。

公开(公告)号：WO1995007348A1

公开(公告)日：1995-03-16

申请号：PCT/US1994010194

申请日：1994-09-07

Applicant: IMCLONE SYSTEMS INCORPORATED ,  GOLDSTEIN, Neil, I. ,  SONGSAKPHISAN, Ratchanee ,  ROSE, Caroline

Inventor： IMCLONE SYSTEMS INCORPORATED

IPC: C12N05/08

CPC classification number: C07K14/71 ,  A61K38/00 ,  A61K2039/505 ,  C07K16/2863 ,  C07K16/2896 ,  C07K2317/34

Abstract: Antibodies that bind specifically to the flk-2 tyrosine kinase receptor may be used to isolate a population of hematopoietic stem cells that expresses the flk-2 receptor.

Abstract translation: 特异性结合flk-2酪氨酸激酶受体的抗体可用于分离表达flk-2受体的造血干细胞群体。

公开(公告)号：WO1994029485A1

公开(公告)日：1994-12-22

申请号：PCT/US1994006690

申请日：1994-06-15

Applicant: IMCLONE SYSTEMS INCORPORATED

Inventor： IMCLONE SYSTEMS INCORPORATED ,  SEGEV, David

IPC: C12Q01/68

CPC classification number: C07H21/00 ,  C12Q1/6816 ,  C12Q2563/179 ,  C12Q2525/113

Abstract: The present invention is directed to a method of amplifying and detecting single or double stranded target nucleic acid molecules. Amplification of the target nucleic acid molecule is accomplished by using at least two chemically modified oligonucleotide probes per target nucleic acid molecule to form a joined oligonucleotide product. Each oligonucleotide probe is comprised of a long and short sequence. The long sequence of each probe hybridizes to adjacent regions of the target nucleic acid molecule. The short sequences of each probe hybridize to each other. Chemical functionality groups attached to the short sequences of each oligonucleotide probe covalently combine linking the probes to form a joined oligonucleotide product. The joined oligonucleotide product is formed without the use of enzymes. The reactivity of the chemical functionality groups on each probe is target dependent. Only when the short sequences of adjacent probes are hybridized to each other are the chemical functionality groups on the probes brought into close enough proximity to form a covalent bond and join the probes to form a joined oligonucleotide product.

Abstract translation: 本发明涉及扩增和检测单链或双链靶核酸分子的方法。 靶核酸分子的扩增通过使用每个靶核酸分子至少两个化学修饰的寡核苷酸探针来形成连接的寡核苷酸产物来实现。 每个寡核苷酸探针由长和短序列组成。 每个探针的长序列与靶核酸分子的相邻区域杂交。 每个探针的短序列彼此杂交。 连接到每个寡核苷酸探针的短序列的化学官能团共价结合连接探针以形成连接的寡核苷酸产物。 在不使用酶的情况下形成连接的寡核苷酸产物。 每个探针上的化学官能团的反应性是目标依赖性的。 只有当相邻探针的短序列彼此杂交时，探针上的化学官能团使其足够接近以形成共价键并连接探针以形成连接的寡核苷酸产物。

公开(公告)号：WO1994002648A1

公开(公告)日：1994-02-03

申请号：PCT/US1993007066

申请日：1993-07-21

Applicant: IMCLONE SYSTEMS INCORPORATED

Inventor： IMCLONE SYSTEMS INCORPORATED

IPC: C12Q01/68

CPC classification number: C12Q1/706 ,  C12Q1/686 ,  C12Q1/6862 ,  C12Q2531/137 ,  C12Q2527/101 ,  C12Q2521/501

Abstract: This invention relates to a process for amplifying any desired specific nucleic acid sequence that exists in a nucleic acid or mixture thereof. The process comprises treating single strand RNA or separated complementary strands of DNA target with a molar excess of oligonucleotide complement pairs in which these oligonucleotide complement pairs have sequences complementary to the target, under hybridizing conditions wherein the gaps between the oligonucleotides bound to the same strand are filled in using no more than three nucleotides, followed by ligation of these oligonucleotides. The process uses oligonucleotide complement pairs selected so that the members of a pair have different melting temperatures. Oligonucleotide members with different melting temperatures permit the members to be selectively hybridized to the target sequence.

Abstract translation: 本发明涉及扩增存在于核酸或其混合物中的任何所需特异性核酸序列的方法。 该方法包括在杂交条件下处理单链RNA或分离的DNA靶互补链与摩尔过量的寡核苷酸补体对，其中这些寡核苷酸补体对具有与靶互补的序列，其中与同一链结合的寡核苷酸之间的间隙为 填充不超过三个核苷酸，然后连接这些寡核苷酸。 该方法使用选择的寡核苷酸补体对，使得一对的成员具有不同的熔融温度。 具有不同熔融温度的寡核苷酸成员允许成员选择性地与目标序列杂交。